S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
NYSEAMERICAN:PLX

Protalix BioTherapeutics - PLX Stock Forecast, Price & News

$1.23
0.00 (0.00%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.21
$1.24
50-Day Range
N/A
52-Week Range
$0.70
$2.00
Volume
99,208 shs
Average Volume
1.69 million shs
Market Capitalization
$57.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PLX stock logo

About Protalix BioTherapeutics (NYSEAMERICAN:PLX) Stock

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Receive PLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

PLX Stock News Headlines

PLX: First Quarter Financial and Operational Review
10 Penny Stocks to Buy in April
PLX: Topline Results from BALANCE
Why Protalix BioTherapeutics Stock Is Soaring
Recap: Protalix BioTherapeutics Q4 Earnings
Protalix Shares Higher After Fabry Disease Data
See More Headlines
Receive PLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

PLX Company Calendar

Last Earnings
5/16/2022
Today
8/12/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:PLX
Previous Symbol
NYSEMKT:PLX
Employees
202
Year Founded
N/A

Profitability

Net Income
$-6,520,000.00
Pretax Margin
-41.62%

Debt

Sales & Book Value

Annual Sales
$62.90 million
Book Value
($0.81) per share

Miscellaneous

Free Float
44,067,000
Market Cap
$57.65 million
Optionable
Optionable
Beta
2.19

Key Executives

  • Mr. Dror Bashan (Age 55)
    Pres, CEO & Director
    Comp: $490.1k
  • Mr. Eyal Rubin M.B.A. (Age 46)
    Sr. VP, CFO, Treasurer & Corp. Sec.
    Comp: $430.56k
  • Dr. Einat Brill-Almon Ph.D. (Age 62)
    Sr. VP & Chief Devel. Officer
    Comp: $430.98k
  • Mr. Yaron Naos (Age 58)
    Sr. VP of Operations
  • Ms. Dafna Shelly M.Sc.
    MBA, VP of HR













PLX Stock - Frequently Asked Questions

How have PLX shares performed in 2022?

Protalix BioTherapeutics' stock was trading at $0.8421 at the beginning of 2022. Since then, PLX stock has increased by 46.1% and is now trading at $1.23.
View the best growth stocks for 2022 here
.

When is Protalix BioTherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our PLX earnings forecast
.

How were Protalix BioTherapeutics' earnings last quarter?

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) announced its quarterly earnings data on Monday, May, 16th. The company reported ($0.05) EPS for the quarter. The business earned $16.09 million during the quarter.

When did Protalix BioTherapeutics' stock split?

Protalix BioTherapeutics shares reverse split before market open on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Protalix BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protalix BioTherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Pluristem Therapeutics (PSTI), Novavax (NVAX), BioLineRx (BLRX), VBI Vaccines (VBIV), Sangamo Therapeutics (SGMO), Verastem (VSTM), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and CRISPR Therapeutics (CRSP).

What is Protalix BioTherapeutics' stock symbol?

Protalix BioTherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

Who are Protalix BioTherapeutics' major shareholders?

Protalix BioTherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital Performance Advisors LLP (0.06%). Insiders that own company stock include Aharon Schwartz, Dror Bashan and Pharma Technologies Ltd Dexcel.
View institutional ownership trends
.

How do I buy shares of Protalix BioTherapeutics?

Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protalix BioTherapeutics' stock price today?

One share of PLX stock can currently be purchased for approximately $1.23.

How much money does Protalix BioTherapeutics make?

Protalix BioTherapeutics (NYSEAMERICAN:PLX) has a market capitalization of $57.89 million and generates $62.90 million in revenue each year. The company earns $-6,520,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis.

How many employees does Protalix BioTherapeutics have?

The company employs 202 workers across the globe.

How can I contact Protalix BioTherapeutics?

Protalix BioTherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The official website for the company is www.protalix.com. The company can be reached via phone at (201) 696-9345, via email at ir@protalix.com, or via fax at 972-4988-9489.

This page (NYSEAMERICAN:PLX) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.